-$0.08 EPS Expected for BioTime, Inc. (BTX) This Quarter

Wall Street brokerages expect that BioTime, Inc. (NASDAQ:BTX) will post ($0.08) earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for BioTime’s earnings. The highest EPS estimate is ($0.06) and the lowest is ($0.09). BioTime posted earnings of ($0.06) per share in the same quarter last year, which suggests a negative year-over-year growth rate of 33.3%. The firm is expected to issue its next earnings results on Thursday, August 1st.

On average, analysts expect that BioTime will report full year earnings of $0.07 per share for the current financial year, with EPS estimates ranging from ($0.01) to $0.14. For the next financial year, analysts expect that the business will report earnings of ($0.33) per share, with EPS estimates ranging from ($0.43) to ($0.23). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover BioTime.

BioTime (NASDAQ:BTX) last posted its quarterly earnings data on Thursday, May 9th. The company reported $0.30 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.36. The firm had revenue of $0.93 million for the quarter, compared to analysts’ expectations of $0.66 million.

Several research analysts have commented on BTX shares. Dawson James reaffirmed a “buy” rating on shares of BioTime in a research note on Thursday, February 7th. HC Wainwright reaffirmed a “buy” rating on shares of BioTime in a research note on Thursday, February 21st.

NASDAQ BTX traded down $0.05 on Thursday, hitting $0.96. 608,334 shares of the stock were exchanged, compared to its average volume of 840,361. BioTime has a 52-week low of $0.66 and a 52-week high of $2.81.

About BioTime

BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.

Further Reading: What is the Coverage Ratio?

Get a free copy of the Zacks research report on BioTime (BTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.